Read about a team of researchers, led by Dr. Benhur Lee, who have identified a broad spectrum antiviral that may be effective against multiple deadly viruses, including HIV-1, Ebola, and Nipah.
The antiretroviral medications used to treat HIV/AIDS currently are organized into five major drug classes.
Reverse Transcriptase (RT) Inhibitors interfere with the critical step during the HIV life cycle known as reverse transcription. During this step, the HIV enzyme RT converts HIV RNA to HIV DNA. There are two main types of RT inhibitors.
Protease Inhibitors interfere with the protease enzyme that HIV uses to produce infectious viral particles.
Fusion/Entry Inhibitors interfere with the virus' ability to fuse with the cellular membrane, thereby blocking entry into the host cell.
Integrase Inhibitors block integrase, the enzyme HIV uses to integrate genetic material of the virus into its target host cell.
Multidrug Combination Products combine drugs from more than one class into a single product. To combat virus strains from becoming resistant to specific antiretroviral drugs, healthcare providers recommend that people infected with HIV take a combination of antiretroviral drugs known as highly active antiretroviral therapy (HAART). Developed by NIAID-supported researchers, the HAART strategy combines drugs from at least two different antiretroviral drug classes.
Another HIV/AIDS drug class known as maturation inhibitors is still in development. If successful, they could potentially prevent HIV from properly assembling and maturing. For example, these treatments could block HIV from forming a protective outer coat or from emerging from human cells.
back to top
Last Updated March 26, 2009
Last Reviewed March 26, 2009